| Prev Close | 62.29 |
| Open | 62.29 |
| Day Low/High | 61.85 / 62.84 |
| 52 Wk Low/High | 31.97 / 63.48 |
| Volume | 92.81K |
| Avg Volume | 521.60K |
Arena Pharmaceuticals Inc. (ARNA)
63.19
0.90
1.40
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 49.57M |
| Market Cap | 3.06B |
| EPS | -0.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Will the Market Go Dead for a While?
The best way to deal with it is to keep on hunting for individual stocks.
The Headlines Are Wrong -- This Is an Extremely Bullish Market
It is two totally different markets when you compare the small-cap action to the big-cap indices.
Small-Caps Are the Place to Be for Now
We are seeing a focus on finding smaller names that may offer interesting valuations and stories.
Market Bifurcation: Individual Stocks Are Acting Better Than the Indices
This underperformance is being caused by pockets of weakness in bigger-cap names.
Reminder: Healthy Stock Markets Decline, Too
The key for the overall market now is that it hold above today's early lows.
Many Names on My Radar
There is no question that we are becoming extended and ripe for some profit taking.
Trump's Drug Pricing Plan Makes Me Want to Play Ball With Biotech Stocks
Sector charts should shape up as worries about prices are finally put to rest.
Having Some Good Luck With Biotech Names
Overall it is still a positive day but the action is sloppy.
Markets Make an Art of Unpredictability
Oil isn't the only reason stocks are higher.
Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern
Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.
Smaller Companies Are Often Some of the Best Trading Vehicles
The challenge of this market is that the upward moves have not been well sustained.
3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold
Rotational action is the main theme Wednesday and good opportunities are out there.
My Biggest Concern About This Stock Market
There's a worrisome scenario that could develop this afternoon.
Here's When You Can Buy Twitter's Stock
There just aren't any pockets of strong momentum right now.
Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
These Stocks Have Changed Direction
Finding bullish and bearish reversals in the market.
Playing Obesity Drugs the ETF Way
Liquidity is key, and one ETF stands above the rest.
Obesity Treatment Shift Could Aid Stocks
Obesity costs are a pain point, which often create good investments.
Break With the Crowd
At major market turns, it is invariably wrong.
The Next Big Thing in Biotech: J.P. Morgan Conference
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
The Next Big Thing In Biotech: 2013 Outlook
Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.
The Next Big Thing In Biotech: Best CEO Candidates
Adam Feuerstein, Sr. Columnist for TheStreet, is assembling candidates for the Best Biotech CEO of 2012 award.
Weight Loss Pills Not a Threat, Says Medifast CEO
Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.
The Next Big Thing in Biotech: Obesity Drugs
Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.
Stocks Under $10: Stealth Drug Play
Portfolio manager David Peltier finds a pharmaceutical name that is quietly growing faster than its peers.
The Next Big Thing in Biotech: FDA Approvals
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
A Trifecta of Wrong
How else can we explain these post-market moves on OK earnings?
